Literature DB >> 2561292

Subject-reported compliance in a chemoprevention trial for familial adenomatous polyposis.

M Berenson1, S Groshen, H Miller, J DeCosse.   

Abstract

A high level of compliance with an assigned treatment regimen is fundamental to accurate assessment of treatment effectiveness in any clinical trial. If compliance is poor, an effective treatment may be confounded by inadequate delivery of the regimen. Although much research has focused on broad aspects of compliance dealing with clinical therapeutic situations, there was a need for further research dealing specifically with adherence issues in a long-term chemoprevention trial since subject motivation in the latter is likely to differ from that of the former. Examining subject-reported compliance over the first 2-year treatment periods of a long-term chemoprevention trial for familial adenomatous polyposis, it was found that (1) compliance decreased over time, (2) fiber compliance was lower than vitamin compliance, and (3) four explanatory variables which may be amenable to individualized study-team interventions emerged as useful prognosticators of fiber compliance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561292     DOI: 10.1007/BF00844869

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  8 in total

1.  Improving patient compliance: a guide for physicians.

Authors:  D Matthews; R Hingson
Journal:  Med Clin North Am       Date:  1977-07       Impact factor: 5.456

2.  Development and validation of the health locus of control (HLC) scale.

Authors:  B S Wallston; K A Wallston; G D Kaplan; S A Maides
Journal:  J Consult Clin Psychol       Date:  1976-08

Review 3.  Compliance with medical regimens: a review of the literature.

Authors:  M V Marston
Journal:  Nurs Res       Date:  1970 Jul-Aug       Impact factor: 2.381

Review 4.  Understanding and improving patient compliance.

Authors:  S A Eraker; J P Kirscht; M H Becker
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

5.  Factors associated with active participation in a Cancer Prevention Clinic.

Authors:  A M Evans; R R Love; B E Meyerowitz; H Leventhal; D R Nerenz
Journal:  Prev Med       Date:  1985-05       Impact factor: 4.018

6.  A randomized trial of ascorbic acid in polyposis coli.

Authors:  H J Bussey; J J DeCosse; E E Deschner; A A Eyers; M L Lesser; B C Morson; S M Ritchie; J P Thomson; J Wadsworth
Journal:  Cancer       Date:  1982-10-01       Impact factor: 6.860

7.  The spectrum of polyposis.

Authors:  S F Sener; H H Miller; J J DeCosse
Journal:  Surg Gynecol Obstet       Date:  1984-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.